Sophie Kervyn
Braine L'alleud, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A.
Journal: EJNMMI research
Published: August 10, 2022
Science-Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels.
Journal: Clinical pharmacology and therapeutics
Published: April 30, 2021
Reprint of: Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.
Journal: Journal of pharmacological and toxicological methods
Published: October 04, 2020
Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.
Journal: Journal of pharmacological and toxicological methods
Published: December 06, 2019
A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
Journal: Epilepsia
Published: December 18, 2018
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Journal: Epilepsia
Published: November 02, 2015
N-alkylprotoporphyrin formation and hepatic porphyria in dogs after administration of a new antiepileptic drug candidate: mechanism and species specificity.
Journal: Toxicological sciences : an official journal of the Society of Toxicology
Published: June 29, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026